RGCB invites applications for PhD biotechnology programme
Candidates with a postgraduate degree in life/agricultural/environmental/veterinary/ pharmaceutical/medical sciences or allied subjects with a minimum of 60 per cent marks in aggregate or equivalent grade in the UGC 10-point scale can apply.
Aspirants should also have a valid JRF (Junior Research Fellowship) of UGC/CSIR/ ICMR/DBT/DST-INSPIRE or any other national-level fellowship for a period of five years offered by the government.
The upper age limit is 26 years. The age limit will be relaxed for SC/ST candidates and the physically-challenged.
The last date for submitting online applications is June 12.
For more details, visit: https://rgcb.res.in/phdadmission2025-Aug/
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
7 hours ago
- NDTV
UGC-NET June Result Declared, Here's The Direct Link To Download Scorecard
UGC-NET June Result 2025: The National Testing Agency (NTA) has declared the result for University Grants Commission-National Eligibility Test (UGC-NET) June Cycle 2025 today, July 21. Candidates who appeared for the examination can check and download the result on the official website, The number of candidates who qualified for the role of JRF and Assistant Professor stands at 5,269, 54,885 for Assistant Professor and admission to PhD, 1,28,179 candidates qualified only for PhD. Here is the direct link to download your scorecard, " UGC-NET June 2025 Scorecard" UGC-NET Exam Statistics 2025 A total of 10,19,751 students had registered for the examination, of which only 7,52,007 candidates appeared. The total number of registered male students were recorded at 4,28,853, of which 3,05,122 had appeared. Female registered candidates were recorded at 5,90,837, of which 4,46,849 had appeared for the examination. UGC-NET June Exam Result: How To Download UGC-NET June Result? Visit the official website, On the homepage, click on "UGC-NET June 2025: Click Here To Download Scorecard". Enter your application number and date of birth. Click on "Submit". Your result will be displayed on the screen. Download and save the result for future reference. The NTA conducts the UGC-NET to determine the eligibility of Indian nationals for the positions of Assistant Professor and/or Junior Research Fellowship (JRF) in Indian universities and colleges. Essentially, it's a gateway for those seeking careers in academia and research. The June exam was held in Computer-Based format across India in several shifts.
Indian Express
10 hours ago
- Indian Express
UGC NET June 2025 Results Announced: Check subject wise cut-offs for JRF, PhD Asst Prof
UGC NET June 2025 Results Announced: The National Testing Agency (NTA) has officially announced the results of the UGC NET June 2025 examination on July 21. The exam, held from June 18 to 21 in Computer-Based Test (CBT) mode, determines candidates' eligibility for the posts of Assistant Professor, Junior Research Fellowship (JRF), and admission to PhD programmes in Indian universities and colleges. Candidates can check their scorecards on the official website at UGC NET June 2025: Over 1.88 lakh candidates qualify A total of 10,19,751 candidates had registered for the June 2025 cycle, of which 7,52,007 appeared. Based on performance and cut-off scores, 5,269 candidates qualified for both JRF and Assistant Professorship, 54,885 qualified for Assistant Professorship and PhD admission, and 1,28,179 candidates qualified for PhD admission only. Candidates are shortlisted based on subject-wise and category-specific cut-off marks. The cut-off score determines eligibility for: –Junior Research Fellowship (JRF) –Assistant Professorship and PhD admission –PhD admission only Below is the subject-wise cut-off for the UR category along with the number of qualified candidates in each category: Candidates who meet the minimum required score in their subject and category are considered qualified for the respective levels. Candidates who have qualified for JRF can apply for funded research positions in universities and are also eligible to apply for Assistant Professor roles. Those who qualified for Assistant Professorship can apply for teaching positions in colleges and universities across India. Candidates shortlisted under the PhD-only category can proceed to apply for admission to doctoral programmes as per the guidelines of respective institutions.
&w=3840&q=100)
Business Standard
17 hours ago
- Business Standard
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
Sun Pharmaceutical Industries has announced that its psoriasis drug ILUMYA (tildrakizumab 100 mg) delivered positive results in two late-stage clinical trials for active psoriatic arthritis (PsA), potentially paving the way for regulatory filings in the United States. The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24. INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose. Consistent safety profile supports regulatory case Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified. ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities. Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals. Targeting IL-23 in chronic inflammatory pathways ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk. Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed. Strategic pipeline strengthens global presence Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
